A Study To Compare The Putative Anxiolytic Effect Of 2 New Drugs In Subjects With Social Anxiety Disorder

PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 27, 2007

Primary Completion Date

January 10, 2008

Study Completion Date

January 10, 2008

Conditions
Social Phobia
Interventions
DRUG

GSK561679 tablet

GSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.

DRUG

GW876008 tablet

GW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).

DRUG

alprazolam

Alprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).

DRUG

Placebo

GW876008 placebo tablets will visually match the active GW876008 tablets. GSK561679 placebo tablets will visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that will visually match the active but containing only a filler.

Trial Locations (8)

08025

GSK Investigational Site, Barcelona

08035

GSK Investigational Site, Barcelona

E-08003

GSK Investigational Site, Barcelona

Unknown

GSK Investigational Site, Barcelona

GSK Investigational Site, Mataro (Barcelona)

08907

GSK Investigational Site, L'Hospitalet de Llobregat

08208

GSK Investigational Site, Sabadell (Barcelona)

08227

GSK Investigational Site, Terrassa - Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY